SLC30A6 and pancreatic adenocarcinoma: Similarly, SLC30A6 (ZnT6) is significantly upregulated in pancreatic adenocarcinoma and contributes to poor prognosis by promoting cancer cell proliferation via ERK1/2, p38 MAPK, and NF-κB signaling pathways [54].